Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00376454 | The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain | PHASE2 | COMPLETED | 113 | — | — | Nov 1, 2002 | Jun 1, 2003 | Feb 12, 2013 | 32 | United States |
| Name | Type | Description |
|---|---|---|
| GW493838 | DRUG | - |
Inclusion criteria (subjects must meet all of the following criteria in order to be eligible for this study): * Females of non-child-bearing potential * diagnosis of peripheral neuropathic pain as a result of: postherpetic neuralgia (PHN) from shingles for at least 3 months duration OR focal neurop...